Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma
Figure 2
Waterfall plots of 18FDG uptake in the tumors after treatment with 188Re-6D2: (a) % change from baseline of ; (b) % change from baseline of SUVmean. Every bar represents an individual patient. Dashed lines at 30% and −30% represent the separation from stable metabolic disease and progressive metabolic disease or partial metabolic response, respectively.
